CN101380329A - 一种精氨酸阿司匹林及其粉针剂的制备方法 - Google Patents
一种精氨酸阿司匹林及其粉针剂的制备方法 Download PDFInfo
- Publication number
- CN101380329A CN101380329A CNA2008101720358A CN200810172035A CN101380329A CN 101380329 A CN101380329 A CN 101380329A CN A2008101720358 A CNA2008101720358 A CN A2008101720358A CN 200810172035 A CN200810172035 A CN 200810172035A CN 101380329 A CN101380329 A CN 101380329A
- Authority
- CN
- China
- Prior art keywords
- aspirin
- arginine
- preparation
- filter
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000004475 Arginine Substances 0.000 title claims abstract description 26
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 238000002347 injection Methods 0.000 title claims abstract description 26
- 239000007924 injection Substances 0.000 title claims abstract description 26
- 239000000843 powder Substances 0.000 title claims abstract description 25
- FXXXGQLMXDIPQA-VWMHFEHESA-N 2-acetyloxybenzoic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CC(=O)OC1=CC=CC=C1C(O)=O FXXXGQLMXDIPQA-VWMHFEHESA-N 0.000 claims abstract description 80
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- 238000003756 stirring Methods 0.000 claims abstract description 25
- 239000000047 product Substances 0.000 claims abstract description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000012043 crude product Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000001556 precipitation Methods 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 24
- 238000001291 vacuum drying Methods 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- 238000005138 cryopreservation Methods 0.000 claims description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 7
- 239000012065 filter cake Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 3
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000009455 aseptic packaging Methods 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000035484 reaction time Effects 0.000 abstract 1
- 239000013049 sediment Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012372 quality testing Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KLCDQSGLLRINHY-UHFFFAOYSA-N 1-phenyldiazenylnaphthalen-2-amine Chemical compound NC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=C1 KLCDQSGLLRINHY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101720358A CN101380329B (zh) | 2008-10-29 | 2008-10-29 | 一种精氨酸阿司匹林及其粉针剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101720358A CN101380329B (zh) | 2008-10-29 | 2008-10-29 | 一种精氨酸阿司匹林及其粉针剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101380329A true CN101380329A (zh) | 2009-03-11 |
CN101380329B CN101380329B (zh) | 2010-11-17 |
Family
ID=40460502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101720358A Expired - Fee Related CN101380329B (zh) | 2008-10-29 | 2008-10-29 | 一种精氨酸阿司匹林及其粉针剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101380329B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101704766A (zh) * | 2009-11-05 | 2010-05-12 | 蚌埠丰原涂山制药有限公司 | 精氨酸阿司匹林及其粉针剂的制备方法 |
CN104693029A (zh) * | 2013-12-05 | 2015-06-10 | 蚌埠丰原涂山制药有限公司 | 一种精氨酸阿司匹林无菌粉的制备方法 |
CN111202842A (zh) * | 2020-02-10 | 2020-05-29 | 刘怡 | 一种治疗玻尿酸血管栓塞的药物组合物 |
WO2021249578A3 (zh) * | 2020-06-07 | 2022-01-27 | 刘力 | 预防治疗哮喘或慢阻肺或过敏性疾病等的药物 |
WO2021249579A3 (zh) * | 2020-06-07 | 2022-01-27 | 刘力 | 预防及治疗感冒或病毒性疾病的药物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2320759A1 (fr) * | 1975-08-11 | 1977-03-11 | Union Pharma Scient Appl | Solution d'acide acetylsalicylique extemporanee injectable |
-
2008
- 2008-10-29 CN CN2008101720358A patent/CN101380329B/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101704766A (zh) * | 2009-11-05 | 2010-05-12 | 蚌埠丰原涂山制药有限公司 | 精氨酸阿司匹林及其粉针剂的制备方法 |
CN104693029A (zh) * | 2013-12-05 | 2015-06-10 | 蚌埠丰原涂山制药有限公司 | 一种精氨酸阿司匹林无菌粉的制备方法 |
CN104693029B (zh) * | 2013-12-05 | 2016-06-08 | 蚌埠丰原涂山制药有限公司 | 一种精氨酸阿司匹林无菌粉的制备方法 |
CN111202842A (zh) * | 2020-02-10 | 2020-05-29 | 刘怡 | 一种治疗玻尿酸血管栓塞的药物组合物 |
WO2021249578A3 (zh) * | 2020-06-07 | 2022-01-27 | 刘力 | 预防治疗哮喘或慢阻肺或过敏性疾病等的药物 |
WO2021249579A3 (zh) * | 2020-06-07 | 2022-01-27 | 刘力 | 预防及治疗感冒或病毒性疾病的药物 |
CN115607556A (zh) * | 2020-06-07 | 2023-01-17 | 刘力 | 预防治疗哮喘或慢阻肺或过敏性疾病等的药物 |
CN115607516A (zh) * | 2020-06-07 | 2023-01-17 | 刘力 | 预防及治疗感冒或病毒性疾病的药物 |
Also Published As
Publication number | Publication date |
---|---|
CN101380329B (zh) | 2010-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101380329B (zh) | 一种精氨酸阿司匹林及其粉针剂的制备方法 | |
US8686053B2 (en) | Alginic acid with low molecular weight, its salts, uses, preparative methods, pharmaceutical compositions and foods | |
CN109678715B (zh) | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 | |
CN101011397A (zh) | 泮托拉唑钠冻干粉针剂及其制备方法 | |
CN103622907B (zh) | 一种布洛芬脂肪乳注射液及其制备方法 | |
CN104367987A (zh) | 兽用黄芪制剂及其制备方法 | |
CN102796078B (zh) | 一种泮托拉唑化合物、制备方法及其药物制剂 | |
CN103301101B (zh) | 2-(2-氟-4-联苯基)-丙酸的新型药物组合物 | |
CN102335114B (zh) | 一种稳定的布洛芬精氨酸注射剂及其制备方法 | |
CN102718693B (zh) | 一种卡络磺钠化合物及其组合物 | |
CN110054606A (zh) | 一种二氢杨梅素-盐酸黄连素药物共晶及制备方法 | |
CN103159817A (zh) | 一种琥珀酸甲泼尼龙的制备方法 | |
CN103058999A (zh) | 一种新型泮托拉唑钠化合物及其药物组合物 | |
CN109847067B (zh) | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 | |
CN106361710A (zh) | 一种乳酸米力农组合物 | |
CN114668716A (zh) | 一种新的间苯三酚注射液制备方法 | |
CN102351888B (zh) | 一种芒果苷元药用配合物及其制备方法与应用 | |
CN101011370A (zh) | α-酮戊二酸组合物的药物制剂及其制备方法和应用 | |
CN102002077A (zh) | 一种唾液酸-蛋氨酸锌新型偶联物、制备工艺及其应用 | |
CN103059000A (zh) | 一种新型奥美拉唑钠化合物及其药物组合物 | |
CN111165829A (zh) | 一种用于刺激胰岛素分泌的食品或保健品 | |
CN103304424A (zh) | 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 | |
CN101380326B (zh) | 葡萄糖酸依诺沙星及其粉针剂的制备方法 | |
CN104173343B (zh) | 一种米力农化合物及含有该化合物的药物组合物 | |
CN103040737A (zh) | 一种含有兰索拉唑化合物的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan Lingkang Pharmaceutical Co., Ltd. Assignor: Hainan Benchuang Pharmaceutical Technology Co., Ltd. Contract record no.: 2011990000937 Denomination of invention: Preparation method of arginine aspirin and powder and injection preparation thereof Granted publication date: 20101117 License type: Exclusive License Open date: 20090311 Record date: 20110928 |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN LINGKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HAINAN BENCHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20130816 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130816 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd. Address before: The new business building No. 48 Hainan 570125 Haikou 26 China World Trade Center Road, room 2601 layer Patentee before: Hainan Benchuang Pharmaceutical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101117 Termination date: 20161029 |
|
CF01 | Termination of patent right due to non-payment of annual fee |